Vascular closure devices: the second decade.

Vascular closure device failure in contemporary practice. JACC Cardiovasc Interv (2012) 1.50

The use of vascular closure devices and impact on major bleeding and net adverse clinical events (NACEs) in balloon aortic valvuloplasty: a sub-analysis of the BRAVO study. Catheter Cardiovasc Interv (2013) 1.40

Bleeding avoidance strategies. Consensus and controversy. J Am Coll Cardiol (2011) 1.20

Vascular access and closure in coronary angiography and percutaneous intervention. Nat Rev Cardiol (2012) 0.92

ARFI ultrasound for in vivo hemostasis assessment postcardiac catheterization, part II: pilot clinical results. Ultrason Imaging (2009) 0.83

Bleeding-avoidance strategies and outcomes in patients ≥80 years of age with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention (from the NCDR CathPCI Registry). Am J Cardiol (2012) 0.79

A retrospective review on feasibility and safety of a new pneumatic compression device for femoral arteriotomy hemostasis. Korean J Radiol (2011) 0.78

A new kaolin-based haemostatic bandage compared with manual compression for bleeding control after percutaneous coronary procedures. Eur Radiol (2011) 0.78

MRI after implantation of a novel femoral closure device following intra-arterial catheterisation: implications for subsequent contrast-enhanced MR angiography. Eur Radiol (2009) 0.77

Successful Retrieval of an Embolized Vascular Closure Device (Angio-Seal(®)) After Peripheral Angioplasty. Cardiovasc Intervent Radiol (2017) 0.75

Comparison of Angioseal and Manual Compression in Patients Undergoing Transfemoral Coronary and Peripheral Vascular Interventional Procedures. Int J Angiol (2015) 0.75

Arterial access and arteriotomy site closure devices. Nat Rev Cardiol (2016) 0.75

Poorly recognized age-related downward deviation of the inguinal ligament. SAGE Open Med (2016) 0.75

Vascular closure devices: begin with the end in mind. J Am Coll Cardiol (2008) 0.75

Arterial access-site complications after use of a vascular closure device related to puncture height. BMC Cardiovasc Disord (2017) 0.75

Simplified swift and safe vascular closure device deployment without a local arteriogram: Single center experience in 2074 consecutive patients. Indian Heart J (2016) 0.75

Central Pseudo-Aneurysm Formation Following Arterial Closure with a StarClose SE Device: When a StarClose Doesn't Completely Close. Am J Case Rep (2016) 0.75

Femoral arterial closure using ProGlide® is more efficacious and cost-effective when ambulating early following cardiac catheterization. Int J Cardiol Heart Vasc (2016) 0.75

Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med (2010) 17.57

Strategies for multivessel revascularization in patients with diabetes. N Engl J Med (2012) 10.79

Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med (2014) 10.54

Clinical end points in coronary stent trials: a case for standardized definitions. Circulation (2007) 10.31

Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med (2015) 9.58

Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med (2013) 8.91

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res (2009) 5.20

Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol (2007) 4.99

Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study. Circulation (2011) 4.95

Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA (2003) 4.74

Trial of everolimus-eluting stents or bypass surgery for coronary disease. N Engl J Med (2015) 4.27

Protected carotid stenting in high-surgical-risk patients: the ARCHeR results. J Vasc Surg (2006) 3.77

Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation (2006) 3.45

Standards for statistical models used for public reporting of health outcomes: an American Heart Association Scientific Statement from the Quality of Care and Outcomes Research Interdisciplinary Writing Group: cosponsored by the Council on Epidemiology and Prevention and the Stroke Council. Endorsed by the American College of Cardiology Foundation. Circulation (2005) 3.38

Health-related quality of life after transcatheter or surgical aortic valve replacement in high-risk patients with severe aortic stenosis: results from the PARTNER (Placement of AoRTic TraNscathetER Valve) Trial (Cohort A). J Am Coll Cardiol (2012) 3.29

Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet (2013) 3.17

Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA (2007) 3.07

Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention. JAMA (2010) 2.98

Comparison of clinical interpretation with visual assessment and quantitative coronary angiography in patients undergoing percutaneous coronary intervention in contemporary practice: the Assessing Angiography (A2) project. Circulation (2013) 2.81

Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol (2012) 2.78

Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. Circulation (2006) 2.72

Cost-effectiveness of transcatheter aortic valve replacement compared with standard care among inoperable patients with severe aortic stenosis: results from the placement of aortic transcatheter valves (PARTNER) trial (Cohort B). Circulation (2012) 2.71

Concordance of physician ratings with the appropriate use criteria for coronary revascularization. J Am Coll Cardiol (2011) 2.62

A blinded, randomized, placebo-controlled trial of percutaneous laser myocardial revascularization to improve angina symptoms in patients with severe coronary disease. J Am Coll Cardiol (2005) 2.56

Cost-effectiveness of transcatheter aortic valve replacement compared with surgical aortic valve replacement in high-risk patients with severe aortic stenosis: results of the PARTNER (Placement of Aortic Transcatheter Valves) trial (Cohort A). J Am Coll Cardiol (2012) 2.56

Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA (2004) 2.55

Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA (2007) 2.49

The frequency and cost of complications associated with coronary artery bypass grafting surgery: results from the United States Medicare program. Ann Thorac Surg (2008) 2.29

Outcomes of optimal or "stent-like"balloon angioplasty in acutemyocardial infarction: the CADILLAC trial. J Am Coll Cardiol (2003) 2.18

Implementation of a statewide system for coronary reperfusion for ST-segment elevation myocardial infarction. JAMA (2007) 2.10

Troponin criteria for myocardial infarction after percutaneous coronary intervention. Arch Intern Med (2012) 2.09

Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation (2009) 2.09

The frequency and incremental cost of major complications among medicare beneficiaries receiving implantable cardioverter-defibrillators. J Am Coll Cardiol (2006) 2.05

Characteristics, management, and outcomes of 5,557 patients age > or =90 years with acute coronary syndromes: results from the CRUSADE Initiative. J Am Coll Cardiol (2007) 2.03

Prevalence and prognostic significance of preprocedural cardiac troponin elevation among patients with stable coronary artery disease undergoing percutaneous coronary intervention: results from the evaluation of drug eluting stents and ischemic events registry. Circulation (2008) 2.01

Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J (2010) 2.00

Preformed donor-specific antibodies and risk of antibody-mediated rejection in repeat renal transplantation. Transplantation (2014) 2.00

Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Thorac Cardiovasc Surg (2012) 1.99

Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial. Am Heart J (2006) 1.98

State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--3. Value Health (2012) 1.90

Use of drug-eluting stents as a function of predicted benefit: clinical and economic implications of current practice. Arch Intern Med (2012) 1.89

Expansion of a regional ST-segment-elevation myocardial infarction system to an entire state. Circulation (2012) 1.88

Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis. Eur Heart J (2014) 1.82

Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level. Circulation (2005) 1.80

Healthcare resource utilization and costs associated with recurrent episodes of atrial fibrillation: the FRACTAL registry. J Cardiovasc Electrophysiol (2007) 1.79

Health-related quality of life after transcatheter aortic valve replacement in inoperable patients with severe aortic stenosis. Circulation (2011) 1.79

Myocardial infarction after carotid stenting and endarterectomy: results from the carotid revascularization endarterectomy versus stenting trial. Circulation (2011) 1.78

Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). J Am Acad Dermatol (2003) 1.76

The Carotid Artery Revascularization and Endarterectomy (CARE) registry: objectives, design, and implications. Catheter Cardiovasc Interv (2008) 1.75

Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document (VARC-2). Eur J Cardiothorac Surg (2012) 1.74

Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials. Circulation (2004) 1.72

Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. Eur Heart J (2012) 1.72

Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial. J Am Coll Cardiol (2011) 1.69

Age and outcomes after carotid stenting and endarterectomy: the carotid revascularization endarterectomy versus stenting trial. Stroke (2011) 1.69

Are drug-eluting stents cost-effective? It depends on whom you ask. Circulation (2006) 1.69

Economic impact of same-day home discharge after uncomplicated transradial percutaneous coronary intervention and bolus-only abciximab regimen. JACC Cardiovasc Interv (2010) 1.67

APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy. J Am Soc Nephrol (2011) 1.67

A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial. J Am Coll Cardiol (2006) 1.65

Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial. J Am Coll Cardiol (2006) 1.65

Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol (2002) 1.62

Drug-eluting stents and the use of percutaneous coronary intervention among patients with class I indications for coronary artery bypass surgery undergoing index revascularization: analysis from the NCDR (National Cardiovascular Data Registry). JACC Cardiovasc Interv (2009) 1.62

Cost-effectiveness of percutaneous coronary intervention with drug eluting stents versus bypass surgery for patients with diabetes mellitus and multivessel coronary artery disease: results from the FREEDOM trial. Circulation (2012) 1.60

Survival benefit with drug-eluting stents in observational studies: fact or artifact? Circ Cardiovasc Qual Outcomes (2011) 1.59

Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol (2006) 1.56

Borderline tuberculoid leprosy in a woman from the state of Georgia with armadillo exposure. J Am Acad Dermatol (2006) 1.56

Economic impact of angina after an acute coronary syndrome: insights from the MERLIN-TIMI 36 trial. Circ Cardiovasc Qual Outcomes (2009) 1.56

Comparison of analytic approaches for the economic evaluation of new technologies alongside multicenter clinical trials. Am Heart J (2003) 1.54

Periprocedural myocardial infarction in a randomized trial of everolimus-eluting and Paclitaxel-eluting coronary stents: frequency and impact on mortality according to historic versus universal definitions. Circ Cardiovasc Interv (2012) 1.52

Differential mortality risk of postprocedural creatine kinase-MB elevation following successful versus unsuccessful stent procedures. J Am Coll Cardiol (2004) 1.52

Do differences in repeat revascularization explain the antianginal benefits of bypass surgery versus percutaneous coronary intervention?: implications for future treatment comparisons. Circ Cardiovasc Qual Outcomes (2012) 1.50

Economic analysis of angiography and preemptive angioplasty to prevent hemodialysis-access thrombosis. Catheter Cardiovasc Interv (2010) 1.50

De novo thrombotic microangiopathy following treatment with sirolimus: report of two cases. Nephrol Dial Transplant (2005) 1.48

Costs and cost-effectiveness of carotid stenting versus endarterectomy for patients at increased surgical risk: results from the SAPPHIRE trial. Catheter Cardiovasc Interv (2011) 1.48

Balancing the risks of restenosis and stent thrombosis in bare-metal versus drug-eluting stents: results of a decision analytic model. J Am Coll Cardiol (2008) 1.48

Pancreas-kidney transplantation is associated with reduced fracture risk compared with kidney-alone transplantation in men with type 1 diabetes. Kidney Int (2013) 1.48

Costs of transradial percutaneous coronary intervention. JACC Cardiovasc Interv (2013) 1.47

Nuisance bleeding with prolonged dual antiplatelet therapy after acute myocardial infarction and its impact on health status. J Am Coll Cardiol (2013) 1.47

Sex-Specific Differences at Presentation and Outcomes Among Patients Undergoing Transcatheter Aortic Valve Replacement: A Cohort Study. Ann Intern Med (2016) 1.46

Repeat revascularization after contemporary percutaneous coronary intervention: an evaluation of staged, target lesion, and other unplanned revascularization procedures during the first year. Circ Cardiovasc Interv (2012) 1.46

Cost-effectiveness of coronary stenting and abciximab for patients with acute myocardial infarction: results from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trial. Circulation (2003) 1.46

Selecting antiplatelet therapy at the time of percutaneous intervention for an acute coronary syndrome: weighing the benefits and risks of prasugrel versus clopidogrel. Circ Cardiovasc Qual Outcomes (2012) 1.44

Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation (2004) 1.43

Claudication: exercise vs endoluminal revascularization (CLEVER) study update. J Vasc Surg (2009) 1.43

The influence of diabetes mellitus on the practice and outcomes of percutaneous coronary intervention in the community: a report from the HCA database. J Invasive Cardiol (2003) 1.43

Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA (2004) 1.42

Influence of age, sex, and atrial fibrillation recurrence on quality of life outcomes in a population of patients with new-onset atrial fibrillation: the Fibrillation Registry Assessing Costs, Therapies, Adverse events and Lifestyle (FRACTAL) study. Am Heart J (2006) 1.42

Current clinical characteristics and economic impact of subacute stent thrombosis. J Invasive Cardiol (2002) 1.42

The "bladder sign"--an important early marker of retroperitoneal hemorrhage. Catheter Cardiovasc Interv (2011) 1.40

Closure devices and vascular complications among percutaneous coronary intervention patients receiving enoxaparin, glycoprotein IIb/IIIa inhibitors, and clopidogrel. Catheter Cardiovasc Interv (2005) 1.40

Vascular hospitalization rates and costs in patients with peripheral artery disease in the United States. Circ Cardiovasc Qual Outcomes (2010) 1.39

Target lesion revascularization after bare-metal or drug-eluting stents: clinical presentations and outcomes. J Invasive Cardiol (2010) 1.39

Multivessel drug-eluting stenting and impact of diabetes mellitus--a report from the EVENT registry. Catheter Cardiovasc Interv (2009) 1.39

Administration of rabbit antithymocyte globulin (thymoglobulin) in ambulatory renal-transplant patients. Transplantation (2003) 1.39

Willingness to pay to eliminate the risk of restenosis following percutaneous coronary intervention: a contingent valuation. Circ Cardiovasc Qual Outcomes (2010) 1.39

In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. JACC Cardiovasc Interv (2009) 1.39

In-hospital and 1-year outcomes with drug-eluting versus bare metal stents in saphenous vein graft intervention: a report from the EVENT registry. Catheter Cardiovasc Interv (2012) 1.38

Current status of kidney and pancreas transplantation in the United States, 1994-2003. Am J Transplant (2005) 1.37

Cost-effectiveness of radiofrequency catheter ablation compared with antiarrhythmic drug therapy for paroxysmal atrial fibrillation. Circ Arrhythm Electrophysiol (2009) 1.33

Use of the Kansas City Cardiomyopathy Questionnaire for monitoring health status in patients with aortic stenosis. Circ Heart Fail (2012) 1.32

Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial. J Am Coll Cardiol (2006) 1.30